Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 3 de 3
1.
Sci Rep ; 14(1): 1582, 2024 01 18.
Article En | MEDLINE | ID: mdl-38238498

Schistosomiasis is caused by parasites of the genus Schistosoma, which infect more than 200 million people. Praziquantel (PZQ) has been the main drug for controlling schistosomiasis for over four decades, but despite that it is ineffective against juvenile worms and size and taste issues with its pharmaceutical forms impose challenges for treating school-aged children. It is also important to note that PZQ resistant strains can be generated in laboratory conditions and observed in the field, hence its extensive use in mass drug administration programs raises concerns about resistance, highlighting the need to search for new schistosomicidal drugs. Schistosomes survival relies on the redox enzyme thioredoxin glutathione reductase (TGR), a validated target for the development of new anti-schistosomal drugs. Here we report a high-throughput fragment screening campaign of 768 compounds against S. mansoni TGR (SmTGR) using X-ray crystallography. We observed 49 binding events involving 35 distinct molecular fragments which were found to be distributed across 16 binding sites. Most sites are described for the first time within SmTGR, a noteworthy exception being the "doorstop pocket" near the NADPH binding site. We have compared results from hotspots and pocket druggability analysis of SmTGR with the experimental binding sites found in this work, with our results indicating only limited coincidence between experimental and computational results. Finally, we discuss that binding sites at the doorstop/NADPH binding site and in the SmTGR dimer interface, should be prioritized for developing SmTGR inhibitors as new antischistosomal drugs.


Multienzyme Complexes , NADH, NADPH Oxidoreductases , Schistosomiasis mansoni , Schistosomiasis , Animals , Child , Humans , Schistosoma mansoni , Crystallography, X-Ray , NADP/metabolism , Schistosomiasis/drug therapy , Binding Sites , Schistosomiasis mansoni/parasitology
2.
J Biol Chem ; 297(2): 100979, 2021 08.
Article En | MEDLINE | ID: mdl-34303703

Schistosomiasis, a neglected tropical disease caused by trematodes of the Schistosoma genus, affects over 250 million people around the world. This disease has been associated with learning and memory deficits in children, whereas reduced attention levels, impaired work capacity, and cognitive deficits have been observed in adults. Strongly correlated with poverty and lack of basic sanitary conditions, this chronic endemic infection is common in Africa, South America, and parts of Asia and contributes to inhibition of social development and low quality of life in affected areas. Nonetheless, studies on the mechanisms involved in the neurological impairment caused by schistosomiasis are scarce. Here, we used a murine model of infection with Schistosoma mansoni in which parasites do not invade the central nervous system to evaluate the consequences of systemic infection on neurologic function. We observed that systemic infection with S. mansoni led to astrocyte and microglia activation, expression of oxidative stress-induced transcription factor Nrf2, oxidative damage, Tau phosphorylation, and amyloid-ß peptide accumulation in the prefrontal cortex of infected animals. We also found impairment in spatial learning and memory as evaluated by the Morris water maze task. Administration of anthelmintic (praziquantel) and antioxidant (N-acetylcysteine plus deferoxamine) treatments was effective in inhibiting most of these phenotypes, and the combination of both treatments had a synergistic effect to prevent such changes. These data demonstrate new perspectives toward the understanding of the pathology and possible therapeutic approaches to counteract long-term effects of systemic schistosomiasis on brain function.


Astrocytes/pathology , Microglia/pathology , Neurodegenerative Diseases/pathology , Schistosoma mansoni/isolation & purification , Schistosomiasis mansoni/complications , Acetylcysteine/pharmacology , Animals , Anthelmintics/pharmacology , Astrocytes/drug effects , Astrocytes/metabolism , Deferoxamine/pharmacology , Disease Models, Animal , Free Radical Scavengers/pharmacology , Male , Mice , Microglia/drug effects , Microglia/metabolism , Morris Water Maze Test/drug effects , Neurodegenerative Diseases/drug therapy , Neurodegenerative Diseases/etiology , Praziquantel/pharmacology , Schistosoma mansoni/drug effects , Schistosoma mansoni/metabolism , Schistosomiasis mansoni/parasitology , Schistosomiasis mansoni/pathology , Siderophores/pharmacology
3.
São Paulo; s.n; 2011. 140 p.
Thesis Pt | SES-SP, SESSP-IBPROD, SES-SP, SESSP-IBACERVO | ID: biblio-1079168

A esquitossomose representa um grande problema em saúde pública, embora negligenciada pelas grandes empresas farmaceuticas. Três genes foram selecionados a partir do transcriptoma do S. mansoni pela possibilidade de estarem presentes na interface parasita-hospedeiro e portanto pelo potencial de serem usados como vacinas. Foi feita uma caracterização molecular destas proteínas no parasita e uma avaliação preliminar dopotencial protetor no modelo murino...


Schistossomiasis is an important disease in public health but neglected by most of the pharmaceutical companies. Three genes were selected from S. mansoni transcriptome to be investigated at the host-parasite interface with furter potential to be used as vaccines. A biological characterization was performed with these three proteins and a preliminary their immunoprotective potential...


Mice , Schistosomiasis mansoni/genetics , Schistosomiasis mansoni/immunology , Schistosomiasis mansoni/drug therapy , Schistosoma mansoni/genetics , Schistosoma mansoni/immunology , Schistosoma mansoni/metabolism , Vaccines/immunology , Vaccines/therapeutic use , Recombinant Proteins/analysis , Recombinant Proteins/genetics
...